Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...
EUR 200 million share buyback begins Schiphol, July 1, 2025 - Aegon today begins a EUR 200 million share buyback that was on May 16, 2025. The share buyback is expected to be completed by December 15, 2025, barring unforeseen circumstances. Aegon has entered into an agreement with its largest shareholder, Vereniging Aegon, to participate in the new EUR 200 million share buyback program. Vereniging Aegon will participate pro-rata in the share buyback program based on its combined common shares and common shares B which represent about 18.4% of the total shareholders’ voting rights that are ...
EUR 150 million share buyback completed Schiphol, July 1, 2025 - Aegon today announces the completion of its EUR 150 million share buyback program that on January 13, 2025. Between January 13, 2025, and June 30, 2025, 25,200,170 common shares were repurchased for a total amount of EUR 150 million at an average price of EUR 5.9641 per share. Aegon will use 6,720,045 common shares to meet its obligations resulting from share-based compensation plans for senior management and cancel the remainder of the repurchased shares in the second half of 2025. For further details, visit our share buyb...
We downgrade Ontex from Buy to HOLD and cut our target price from €13.83 to €8.2 following a change in primary analyst. We expect 2025 to be another year of heavy restructuring, leading to peak capex which is required, in our view, to modernise its industrial footprint and enable it to compete profitably on larger contracts going forwards. We see this limiting Ontex's organic growth in the short term to 2.7% in FY25F, despite capex on sales of c.6%. Although €115m in divestment proceeds is expec...
UCB announced positive Phase 3 results for Fintepla in treating CDKL5 deficiency disorder (CDD), a rare and severe early-onset epileptic condition with limited treatment options. The randomized, placebo-controlled study in patients aged 1–35 met its primary and secondary endpoints, showing a significant reduction in countable motor seizures and a favourable safety profile. UCB plans to announce the full dataset at an upcoming conference and seek regulatory approval promptly. This marks Fintepla'...
Ontex Group NV announces the redemption of the outstanding 3.500% senior notes due 2026 Regulated information Aalst, Belgium, June 26, 2025 – Ontex Group NV (the “Issuer”) is pleased to announce that, pursuant to an unconditional notice of redemption dated June 26, 2025, it has notified the holders of the 3.500% Senior Notes due 2026 (ISIN: BE6329443962) (the “Notes”), that it will redeem all of its remaining outstanding Notes, plus accrued and unpaid interest and additional amounts, if any, on July 15, 2025. Following the cash tender offer launched in March and concluded in April 2026, wh...
Ontex Group NV kondigt de aflossing aan van diens uitstaande 3,500% senior obligaties met vervaldag in 2026 Gereglementeerde informatie Aalst, België, 26 juni 2025 – Ontex Group NV (de “Emittent”) is verheugd aan te kondigen dat, overeenkomstig een onvoorwaardelijke kennisgeving van aflossing gedateerd 26 juni 2025, het de houders van de 3,500% Senior Notes met vervaldatum in 2026 (ISIN: BE6329443962) (de “Notes”) heeft geïnformeerd dat het al zijn resterende uitstaande Notes zal aflossen op 15 juli 2025, inclusief opgebouwde en onbetaalde rente en bijkomende bedragen, indien van toepassin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.